The funding will be used to move the ARGO-HT research platform into an FDA-cleared system to support the development of diagnostic tests.
The firm said that the unsecured $1.5 billion revolving credit facility through 2030 replaces another $1.5 billion credit facility through 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback